BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Sorriso Pharmaceuticals Completes Enrollment in Phase 1b Clinical Trial of Patients with Ulcerative Colitis
News | 09. 03. 2024
Sorriso Pharmaceuticals
SALT LAKE CITY, UT, UNITED STATES, September 3, 2024 -- Sorriso Pharmaceuticals, a biopharmaceutical company developing novel oral antibodies for immune-mediated disease, today announced the completion of patient enrollment in its Phase 1b clinical trial evaluating the safety, tolerability, and preliminary efficacy of SOR102, a bispecific oral dual-acting biologic for the treatment of ulcerative colitis.
